Profile data is unavailable for this security.
About the company
Harbin Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing, wholesale and retail of pharmaceutical. The Company is mainly engaged in two businesses. The pharmaceutical industry business is mainly engaged in the research, development and manufacturing of chemical raw materials, chemical preparations, biological preparations, traditional Chinese medicine and health care products. The pharmaceutical commercial business is mainly engaged in pharmaceutical commercial wholesale business and pharmaceutical commercial retail business. The Company's products mainly include zinc gluconate oral solution, calcium iron zinc oral solution, compound calcium gluconate oral solution, amoxicillin capsules and Shuanghuanglian oral solution. The Company's products are mainly used in digestive, respiratory, anti-infectious, cardiovascular and cerebrovascular and anti-tumor treatment fields.
- Revenue in CNY (TTM)16.22bn
- Net income in CNY613.05m
- Incorporated1991
- Employees9.85k
- LocationHarbin Pharmaceutical Group Co LtdNo. 7 Qunli Avenue, Daoli DistrictHAERBIN 150070ChinaCHN
- Phone+86 45 151870077
- Fax+86 45 151870077
- Websitehttps://www.hayao.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurisco Pharmaceutical Co Ltd | 1.43bn | 340.67m | 8.54bn | 1.52k | 25.89 | 3.77 | -- | 5.98 | 0.8124 | 0.8124 | 3.40 | 5.58 | 0.4716 | 1.14 | 4.72 | 939,069.60 | 11.23 | 12.40 | 13.35 | 14.33 | 57.16 | 51.26 | 23.81 | 23.05 | 2.82 | -- | 0.3049 | 25.15 | 25.24 | 17.02 | 37.23 | 16.16 | 26.54 | -- |
| Shenzhen Chipscreen Biosciences Co Ltd | 656.24m | -70.33m | 8.60bn | 1.06k | -- | 5.24 | -- | 13.11 | -0.1709 | -0.1709 | 1.60 | 4.03 | 0.2022 | 2.34 | 4.47 | 620,847.90 | -2.17 | 1.32 | -2.44 | 1.54 | 86.24 | 93.29 | -10.72 | 6.97 | 2.76 | -0.5584 | 0.441 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 2.86bn | -24.94m | 8.76bn | 2.89k | -- | 1.35 | -- | 3.07 | -0.0074 | -0.0074 | 0.8379 | 1.89 | 0.2476 | 2.17 | 4.52 | 990,180.10 | -0.3138 | 2.26 | -0.4836 | 3.38 | 42.33 | 72.05 | -1.27 | 7.27 | 2.39 | -- | 0.1767 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| Shanghai Yizhong Pharmaceutical Co Ltd | 250.66m | 65.60m | 8.90bn | 43.00 | 136.74 | 6.16 | -- | 35.50 | 0.3163 | 0.3163 | 1.21 | 7.02 | 0.1669 | 0.5372 | 2.00 | 5,829,320.00 | 4.37 | -0.9181 | 4.57 | -0.9485 | 94.00 | 93.19 | 26.17 | -6.11 | 17.37 | -- | 0.0075 | -- | 52.68 | -- | 13.09 | -- | 20.44 | -- |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 1.24bn | 136.56m | 9.23bn | 1.81k | 67.57 | 5.89 | -- | 7.44 | 0.279 | 0.279 | 2.53 | 3.20 | 0.5011 | 0.5647 | 2.60 | 684,557.40 | 6.04 | -2.10 | 8.71 | -3.16 | 72.21 | 69.74 | 12.05 | -6.00 | 0.9873 | 21.00 | 0.0267 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
| Youcare Pharmaceutical Group Co Ltd | 4.23bn | 242.25m | 9.27bn | 3.18k | 38.28 | 2.53 | -- | 2.19 | 0.5382 | 0.5382 | 9.39 | 8.14 | 0.7221 | 2.33 | 5.37 | 1,330,727.00 | 4.11 | 7.11 | 6.04 | 11.65 | 58.62 | 64.14 | 5.70 | 8.07 | 1.52 | 105.13 | 0.1939 | 60.95 | -7.61 | 1.05 | -44.84 | -7.16 | 23.40 | -- |
| Harbin Pharmaceutical Group Co., Ltd. | 16.22bn | 613.05m | 9.29bn | 9.85k | 15.26 | 1.78 | -- | 0.573 | 0.2418 | 0.2418 | 6.38 | 2.07 | 1.15 | 6.29 | 3.47 | 1,646,115.00 | 4.78 | 0.7414 | 12.56 | 1.89 | 27.60 | 23.87 | 4.15 | 0.7294 | 1.11 | 36.80 | 0.3633 | 0.00 | 11.93 | 7.41 | -14.88 | 2.69 | -5.38 | -- |
| North China Pharmaceutical Co Ltd | 9.71bn | 79.38m | 9.35bn | 10.16k | 117.13 | 1.74 | -- | 0.9634 | 0.0465 | 0.0465 | 5.68 | 3.13 | 0.4492 | 2.67 | 4.34 | 955,385.00 | 0.6731 | -0.2978 | 1.54 | -0.7042 | 29.79 | 35.73 | 1.50 | -0.5985 | 0.5609 | 1.64 | 0.6482 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| Nanjing Vazyme Biotech Co Ltd | 1.40bn | 23.59m | 9.74bn | 2.70k | 395.90 | 2.44 | -- | 6.95 | 0.0615 | 0.0615 | 3.84 | 9.97 | 0.2644 | 1.06 | 3.57 | 519,483.10 | 0.4122 | 13.16 | 0.5237 | 15.92 | 70.21 | 70.50 | 1.56 | 23.92 | 4.17 | -- | 0.1436 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Chongqing Genrix Biophrmctcl Co Ltd | 13.56m | -779.42m | 9.98bn | 547.00 | -- | 4.24 | -- | 736.05 | -2.13 | -2.13 | 0.037 | 6.42 | 0.0039 | 0.1009 | 1.37 | 24,790.27 | -22.22 | -- | -23.06 | -- | 55.87 | -- | -5,747.82 | -- | 18.62 | -- | 0.2454 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
Data as of Nov 26 2024. Currency figures normalised to Harbin Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 7.89m | 0.31% |
| The Vanguard Group, Inc.as of 31 Oct 2024 | 6.50m | 0.26% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 4.22m | 0.17% |
| SWS MU Fund Management Co., Ltd.as of 30 Jun 2024 | 660.10k | 0.03% |
| Nanhua Fund Management Co. Ltd.as of 30 Jun 2024 | 584.30k | 0.02% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 549.50k | 0.02% |
| Robeco Institutional Asset Management BVas of 30 Sep 2024 | 373.20k | 0.02% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 293.50k | 0.01% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2024 | 279.90k | 0.01% |
| Zhejiang Zheshang Securities Asset Management Co., Ltd.as of 30 Jun 2024 | 242.40k | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
